Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

BACKGROUND: Multiple trials have confirmed that romiplostim could increase platelet count in individuals with primary immune thrombocytopenia (ITP), but no related study has assessed Chinese patients. OBJECTIVES: To assess the effectiveness of romiplostim as a second-line treatment of persistent or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hu, Zhou, Jianfeng, Wu, Depei, Ma, Liping, Du, Xin, Niu, Ting, Yang, Renchi, Liu, Jing, Zhang, Feng, Shi, Qingzhi, Wang, Xiuli, Jing, Hongmei, Li, Junmin, Wang, Xin, Cui, Zhongguang, Zhou, Zeping, Hou, Ming, Shao, Zonghong, Jin, Jie, Li, Wenqian, Ren, Hanyun, Hu, Jianda, Shen, Jianliang, Liu, Li, Zeng, Yun, Zhou, Jin, Liu, Xin, Shen, Yunfeng, Ding, Kai, Taira, Tadaaki, Cai, Huacong, Zhao, Yongqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439391/
https://www.ncbi.nlm.nih.gov/pubmed/37601010
http://dx.doi.org/10.1016/j.rpth.2023.100192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439391/
https://www.ncbi.nlm.nih.gov/pubmed/37601010
http://dx.doi.org/10.1016/j.rpth.2023.100192

Ejemplares similares